The Zacks Analyst Blog Highlights: Co-Diagnostics, Regeneron Pharmaceuticals, Netflix, Norwegian Cruise Line And American Airlines

For Immediate Release

Chicago, IL – March 4, 2020 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Co-Diagnostics, Inc. (NASDAQ:CODX) , Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) , Netflix, Inc. (NASDAQ:NFLX) , Norwegian Cruise Line Holdings Ltd. (NYSE:NCLH) and American Airlines Group Inc. (NASDAQ:AAL) .

Here are highlights from Tuesday’s Analyst Blog:

Best- and Worst-Performing Stocks from Coronavirus Outbreak

The coronavirus outbreak and its subsequent impact on corporate profit margins and the global economy continue to dominate the headlines. U.S. stocks endured their worst weekly slide on Feb 28 since October 2008. In fact, all the major indexes closed in the correction territory last Thursday, and several well-known companies like Nike (NYSE:NKE), United Airlines and Mastercard (NYSE:MA) issued earnings and revenue warnings.

Goldman Sachs’ chief global equity strategist, Peter Oppenheimer, added that “in the nearer term… we believe the greater risk is that the impact of the coronavirus on earnings may well be underestimated in current stock prices, suggesting that the risks of a correction are high.”

But U.S. stocks did make a roaring comeback on Mar 2 after investors started to believe that central banks around the world, including the Fed, would take actions to put a check on the steep losses. Most of them are widely expecting a coordinated global effort to trim rates to stimulate the economy.

Australian central bank’s governor in the meantime acknowledged that the coronavirus outbreak does have a “significant effect” on the country’s economy and any move to ease monetary policy will certainly “provide additional support to employment and economic activity.”

However, let’s admit we cannot completely write off the adverse impact of the outbreak, and the U.S. stock market will continue to gyrate in the days to come. After all, the disease continues to spread. The virus has reached countries beyond China, including the United States, Italy, Germany, Iran and South Korea.

Nonetheless, these stocks are the big winners and losers since the coronavirus outbreak stalled the U.S. bull market —

Stocks That Defied the Coronavirus Pandemic

Co-Diagnostics, Inc., Regeneron Pharmaceuticals, Inc. and Netflix, Inc. are some of the prominent names that have soared 1889.5%, 33%, 23.8% and 17.8%, respectively, so far this year amid the coronavirus rout. Take a look —

Molecular diagnostics company Co-Diagnostics has introduced an easier-to-use molecular diagnostic test known as the Logix Smart Coronavirus COVID-19 test. And the company has received a CE mark approval from the European Union to make this test commercially available.

With the outbreak spreading rapidly, the need for molecular diagnostic tests will increase, and in turn, boost Co-Diagnostics’ revenues. The company currently has a Zacks Rank #2 (Buy). The Zacks Consensus Estimate for its current-year earnings has moved up 66.7% over the past 60 days. What’s more, the company’s expected earnings growth rate for the next quarter is 44.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Clinical stage biotechnology company, Moderna has manufactured a new vaccine for coronavirus treatment. Unlike DNA-based treatments, Moderna focuses on developing mRNA treatments, which should help in treating the virus better. DNA-based treatments generally require the nucleus of the cell but mRNA can be found across the cell which makes it easily accessible.

Moderna, by the way, has been pretty impressive. After getting to know the virus’ genetic composition, it took the company less than two months to develop the vaccine. Moderna currently has a Zacks Rank #2. The Zacks Consensus Estimate for its current-year earnings has moved up 6.2% over the past 60 days. The company’s expected earnings growth rate for the current and next quarter is 7.5% and 9.8%, respectively.

Based on Ebola knowledge, Regeneron Pharmaceuticals is making a vaccine to tackle COVID-19. Regeneron’s initiative to prepare such a potent weapon helped its shares increase leaps and bounds this year especially when compared to the mere 2.5% it brought in for the last 12 months. By the way, the company is doing well in itself. Its fourth-quarter results were impressive, wherein both sales and earnings beat estimates on label expansion of Eylea and Dupixent.

Regeneron currently possesses a Zacks Rank #1. The Zacks Consensus Estimate for its current-year earnings has moved up 6.4% over the past 60 days. The company’s expected earnings growth rate for the current and next quarter is 35.5% and 15.1%, respectively.

Apart from biotech stocks, Netflix’s shares have gained because the company has an established business models and is fundamentally strong enough to provide hedge against any downfall. Firstly, it primarily provides streaming services, so any lockdown in response to the coronavirus outbreak won’t have any impact on its subscriber growth. In fact, Netflix added 8.8 million subscribers internationally last quarter, surpassing analysts’ expectations by more than a million.

Netflix’s subscriber growth was mostly driven by content strength, focus on originals across various genres and languages, rapid international expansion and partnerships with telcos. Meanwhile, Netflix entered this year’s Oscars with 24 nominations, and walked away with two wins. Such wins will certainly help Netflix lure and retain subscribers in the face of challenges from rival services like Disney+ and Apple (NASDAQ:AAPL) TV+.

Netflix currently has a Zacks Rank #2. The Zacks Consensus Estimate for its current-year earnings has moved 10.6% north over the past 60 days. The company’s expected earnings growth rate for the current quarter and year is a promising 119.7% and 46.7%, respectively (read more: Coronavirus Fears Holding You Back? 3 Smart Ways to Invest).

Not So Lucky Ones

With so many people affected across the globe by the spread of the contagious disease, travel-related stocks were hit hard. Cruise operators were among the worst hit. Shares of Norwegian Cruise Line Holdings Ltd. have tanked 39.1% on a year-to-date basis. After all, the company has generated 2% of its revenues from China over the last 12 months. Airline stocks were also collectively affected, and most prominently American Airlines Group Inc.’s shares have slipped 34.2% so far this year.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

http://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.